RAPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RAPT Therapeutics is not a good buy for a beginner, long-term investor at this time. The stock is trading near its acquisition price of $58 per share, and the upside potential is minimal due to the finalized acquisition agreement with GSK. Analysts have downgraded the stock to neutral or hold ratings, and there are no significant catalysts or growth opportunities in the near term.
The stock is currently overbought with an RSI of 80.645, and the MACD is negative at -0.835, indicating a lack of upward momentum. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the price is trading near its resistance level of $58, leaving little room for further gains.
Great Point Partners recently acquired shares, reflecting some institutional confidence. GSK's acquisition of RAPT at $58 per share provides a guaranteed exit price for current shareholders.
All analysts have downgraded the stock to neutral or hold ratings following the acquisition announcement. Hedge funds are selling heavily, with a 392% increase in selling activity last quarter. The company's financials show no revenue growth and a significant net loss.
In Q3 2025, RAPT reported no revenue growth (0% YoY) and a net loss of $17.58 million, down 4.62% YoY. EPS dropped significantly by 82.85% YoY to -0.65, indicating weak financial performance.
Analysts have downgraded RAPT to neutral or hold ratings with a $58 price target, aligning with the acquisition price set by GSK. There is no upside potential beyond the acquisition price.
